Dataset Viewer
trial_id
stringlengths 11
11
| question
stringlengths 154
5.24k
| options
dict | answer
stringclasses 4
values | trials
sequencelengths 4
4
| id
int64 0
27.3k
| split
stringclasses 2
values |
|---|---|---|---|---|---|---|
NCT00000112 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The prevalence of obesity in children is reaching epidemic proportions. Excess adiposity is more than just a cosmetic problem, having substantial metabolic consequences. Insulin resistance, hyperinsulinemia, impaired glucose tolerance, and frank diabetes are often seen in obese children. In this study the prevalence of impaired glucose (carbohydrate) tolerance in lean children with a family history of diabetes and obese children with acanthosis nigricans with or without a family history of diabetes mellitus will be studied.
| {
"A": "Arm Label: sorafenib group; Type: ACTIVE_COMPARATOR; Interventions: Drug: sorafenib | Arm Label: radioembolization group; Type: ACTIVE_COMPARATOR; Interventions: Drug: SIR-Sphere | Intervention Type: DRUG; Name: sorafenib; Assigned to Arm(s): sorafenib group | Intervention Type: DRUG; Name: SIR-Sphere; Assigned to Arm(s): radioembolization group",
"B": "Arm Label: Sorafenib, Multikinase Inhibitor, Tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib tosylate | Arm Label: SIR-Spheres, Microspheres, Device; Type: ACTIVE_COMPARATOR; Interventions: Device: SIR-Spheres | Intervention Type: DEVICE; Name: SIR-Spheres; Assigned to Arm(s): SIR-Spheres, Microspheres, Device | Intervention Type: DRUG; Name: Sorafenib tosylate; Assigned to Arm(s): Sorafenib, Multikinase Inhibitor, Tablet",
"C": "Intervention Type: DEVICE; Name: Yttrium-90 microspheres (Therasphere MDS Nordion); Assigned to Arm(s): N/A",
"D": "N/A"
} | D | [
"NCT01482442",
"NCT01135056",
"NCT00910572",
"NCT00000112"
] | 0 | train |
NCT00000113 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Myopia Evaluation Trial (COMET)
Brief Summary: To evaluate whether progressive addition lenses (PALs) slow the rate of progression of juvenile-onset myopia (nearsightedness) when compared with single vision lenses, as measured by cycloplegic autorefraction. An additional outcome measure is axial length, as measured by A-scan ultrasonography.
To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses).
| {
"A": "Intervention Type: DRUG; Name: Atropine Eye drops; Assigned to Arm(s): N/A",
"B": "Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses",
"C": "Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL",
"D": "Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses"
} | B | [
"NCT00371124",
"NCT00000113",
"NCT00335049",
"NCT00977236"
] | 1 | train |
NCT00000113 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Correction of Myopia Evaluation Trial (COMET)
Brief Summary: To evaluate whether progressive addition lenses (PALs) slow the rate of progression of juvenile-onset myopia (nearsightedness) when compared with single vision lenses, as measured by cycloplegic autorefraction. An additional outcome measure is axial length, as measured by A-scan ultrasonography.
To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses).
| {
"A": "Intervention Type: DEVICE; Name: Polymethyl Methacrylate-Silicone Contact Lenses; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Polymethyl Methacrylate Contact Lenses; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A",
"C": "Arm Label: Progressive Addition Lenses (PALs); Type: EXPERIMENTAL; Interventions: Other: Progressive Addition Lenses | Arm Label: Single Vision Lenses; Type: ACTIVE_COMPARATOR; Interventions: Other: single vision lenses | Intervention Type: OTHER; Name: Progressive Addition Lenses; Assigned to Arm(s): Progressive Addition Lenses (PALs) | Intervention Type: OTHER; Name: single vision lenses; Assigned to Arm(s): Single Vision Lenses",
"D": "Arm Label: Orthokeratology lenses; Type: EXPERIMENTAL; Interventions: Device: Orthokeratology lenses | Arm Label: Single-vision spectacle lenses; Type: OTHER; Interventions: Device: Single-vision spectacle lenses | Intervention Type: DEVICE; Name: Orthokeratology lenses; Assigned to Arm(s): Orthokeratology lenses | Intervention Type: DEVICE; Name: Single-vision spectacle lenses; Assigned to Arm(s): Single-vision spectacle lenses"
} | C | [
"NCT00000123",
"NCT00457717",
"NCT00000113",
"NCT00977236"
] | 2 | train |
NCT00000123 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the relative efficacy of orthokeratology, primarily by assessment of changes in central corneal thickness, astigmatism, visual acuity, endothelial cell density, and corneal curvature.
To evaluate the relative safety of orthokeratology, primarily by assessment of changes in central corneal thickness, astigmatism, visual acuity, endothelial cell density, induced corneal edema, and epithelial staining.
To assess the duration of any orthokeratology treatment effect.
To study the mechanisms by which refractive error and visual acuity changes occur, in particular the contribution that comes from changes in corneal curvature and shape.
To determine whether there were any predisposing ocular factors that could be used to predict which subjects will experience changes or complications.
| {
"A": "Intervention Type: DEVICE; Name: Bifocal Spectacle Lenses; Assigned to Arm(s): N/A",
"B": "Intervention Type: DEVICE; Name: Polymethyl Methacrylate-Silicone Contact Lenses; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Polymethyl Methacrylate Contact Lenses; Assigned to Arm(s): N/A",
"C": "Arm Label: Single-vision glasses; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Orthokeratology with normal compression factor; Type: SHAM_COMPARATOR; Interventions: Device: Orthokeratology | Arm Label: Orthokeratology with increased compression factor; Type: ACTIVE_COMPARATOR; Interventions: Device: Orthokeratology | Intervention Type: DEVICE; Name: Orthokeratology; Assigned to Arm(s): Orthokeratology with increased compression factor, Orthokeratology with normal compression factor",
"D": "Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A"
} | B | [
"NCT00000128",
"NCT00000123",
"NCT02643342",
"NCT00457717"
] | 3 | train |
NCT00000128 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To test the hypothesis that correction with bifocal spectacle lenses rather than single-vision lenses will slow the progression of myopia in children with near-point esophoria. The primary outcome variable is cycloplegic refraction as measured with an automated refractor. Axial length is measured with ultrasound in order to test the corollary hypothesis that use of bifocals will slow ocular growth in these myopic children. We will also examine the amount of close work performed by subjects and the degree of parental myopia as factors that may influence myopia progression.
| {
"A": "Intervention Type: DEVICE; Name: Bifocal Spectacle Lenses; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: 7-methylxanthine; Assigned to Arm(s): N/A",
"C": "Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Outdoor activity; Type: EXPERIMENTAL; Interventions: Behavioral: Outdoor activity | Intervention Type: BEHAVIORAL; Name: Outdoor activity; Assigned to Arm(s): Outdoor activity",
"D": "Arm Label: Bifocal spectacles; Type: ACTIVE_COMPARATOR; Interventions: Device: Bifocal spectacles | Arm Label: Prismatic bifocals; Type: ACTIVE_COMPARATOR; Interventions: Device: Prismatic bifocal spectacles | Arm Label: Single vision spectacles; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bifocal spectacles; Assigned to Arm(s): Bifocal spectacles | Intervention Type: DEVICE; Name: Prismatic bifocal spectacles; Assigned to Arm(s): Prismatic bifocals"
} | A | [
"NCT00000128",
"NCT00263471",
"NCT00848900",
"NCT00787579"
] | 4 | train |
NCT00000150 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.
To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).
To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.
| {
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: oseltamivir + zanamivir | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir + zanamivir's placebo | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: oseltamivir's placebo + zanamivir | Intervention Type: DRUG; Name: oseltamivir + zanamivir; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oseltamivir + zanamivir's placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: oseltamivir's placebo + zanamivir; Assigned to Arm(s): 3",
"B": "Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A",
"C": "Arm Label: Pegcetacoplan 15 mg/100 µL Monthly for 12 months; Type: EXPERIMENTAL; Interventions: Drug: Pegcetacoplan | Arm Label: Pegcetacoplan 15 mg/100 µL EOM for 12 months; Type: EXPERIMENTAL; Interventions: Drug: Pegcetacoplan | Arm Label: Sham Monthly for 12 months; Type: SHAM_COMPARATOR; Interventions: Other: Sham Procedure | Arm Label: Sham EOM for 12 months; Type: SHAM_COMPARATOR; Interventions: Other: Sham Procedure | Intervention Type: DRUG; Name: Pegcetacoplan; Assigned to Arm(s): Pegcetacoplan 15 mg/100 µL EOM for 12 months, Pegcetacoplan 15 mg/100 µL Monthly for 12 months | Intervention Type: OTHER; Name: Sham Procedure; Assigned to Arm(s): Sham EOM for 12 months, Sham Monthly for 12 months",
"D": "Arm Label: Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline"
} | B | [
"NCT00799760",
"NCT00000150",
"NCT02503332",
"NCT00935883"
] | 5 | train |
NCT00000150 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.
To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).
To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.
| {
"A": "Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A",
"D": "Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A"
} | D | [
"NCT00056836",
"NCT00061594",
"NCT00090623",
"NCT00000150"
] | 6 | train |
NCT00000150 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Submacular Surgery Trials (SST)
Brief Summary: To determine whether surgical removal of subfoveal choroidal neovascularization (CNV) and associated hemorrhage in patients with age-related macular degeneration (AMD), the ocular histoplasmosis syndrome (OHS), or idiopathic CNV stabilizes or improves vision more often than observation.
To determine how surgical removal compared to observation of subfoveal CNV due to AMD, OHS, or idiopathic causes changes the patient's perception of health- and vision-related "quality of life," as measured by telephone interview using the Medical Outcomes Survey Short Form-36 (MOS SF-36) instrument, the Hospital Anxiety and Depression Scale, and the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).
To determine whether randomized trials of surgery are warranted for patients with subfoveal CNV associated with age-related macular degeneration not suitable for laser treatment.
| {
"A": "Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A",
"B": "Arm Label: bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): bevacizumab",
"C": "Intervention Type: PROCEDURE; Name: Subfoveal Choroidal Neovascularization Removal; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A"
} | C | [
"NCT00056836",
"NCT01327222",
"NCT00000150",
"NCT00090623"
] | 7 | train |
NCT00000152 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982.
To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E.
To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
| {
"A": "Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene",
"B": "Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Beta-Carotene; Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin and mineral supplement, Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Intervention Type: DRUG; Name: vitamin and mineral supplement; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Escherichia coli Endotoxin (LPS); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 100% O2; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: nitroglycerin; Assigned to Arm(s): 1, 2",
"D": "Arm Label: OT-551 antioxidant eye drop; Type: EXPERIMENTAL; Interventions: Drug: OT-551 antioxidant eye drop | Intervention Type: DRUG; Name: OT-551 antioxidant eye drop; Assigned to Arm(s): OT-551 antioxidant eye drop"
} | B | [
"NCT00270647",
"NCT00000152",
"NCT00431691",
"NCT00306488"
] | 8 | train |
NCT00000170 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available
Extended Follow up of Study Patients
* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
| {
"A": "Intervention Type: DEVICE; Name: 6 hours occlusion by patching; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 12 hours occlusion by patching; Assigned to Arm(s): N/A",
"B": "Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching",
"C": "Arm Label: patching (occlusion therapy); Type: ACTIVE_COMPARATOR; Interventions: Other: patching | Arm Label: binocular games; Type: EXPERIMENTAL; Interventions: Other: binocular games | Intervention Type: OTHER; Name: patching; Assigned to Arm(s): patching (occlusion therapy) | Intervention Type: OTHER; Name: binocular games; Assigned to Arm(s): binocular games",
"D": "Arm Label: Binocular Treatment; Type: EXPERIMENTAL; Interventions: Device: iPad® | Arm Label: Patching Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Patching 2 hours per day, 7 days per week | Intervention Type: DEVICE; Name: iPad®; Assigned to Arm(s): Binocular Treatment | Intervention Type: OTHER; Name: Patching 2 hours per day, 7 days per week; Assigned to Arm(s): Patching Treatment"
} | B | [
"NCT00274664",
"NCT00000170",
"NCT02365090",
"NCT02200211"
] | 9 | train |
NCT00000170 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available
Extended Follow up of Study Patients
* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
| {
"A": "Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching",
"B": "Intervention Type: DEVICE; Name: 6 hours occlusion by patching; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 12 hours occlusion by patching; Assigned to Arm(s): N/A",
"C": "Arm Label: Near activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Near activities | Arm Label: Distance activities; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch, Procedure: Distance activities | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Distance activities, Near activities | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Near activities | Intervention Type: PROCEDURE; Name: Distance activities; Assigned to Arm(s): Distance activities",
"D": "Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Procedure: Near activities | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Atropine, Patching"
} | A | [
"NCT00000170",
"NCT00274664",
"NCT00315198",
"NCT00315328"
] | 10 | train |
NCT00000170 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available
Extended Follow up of Study Patients
* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
| {
"A": "Arm Label: Intensive; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Drug: Atropine | Arm Label: Weaning; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Drug: Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Intensive | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Intensive | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Weaning | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Weaning",
"B": "Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching",
"C": "Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: spectacles; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atropine; Assigned to Arm(s): N/A",
"D": "Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Patching, Procedure: Near activities | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine, Procedure: Near activities | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Patching; Assigned to Arm(s): Patching | Intervention Type: PROCEDURE; Name: Near activities; Assigned to Arm(s): Atropine, Patching"
} | B | [
"NCT00506675",
"NCT00000170",
"NCT00094692",
"NCT00315328"
] | 11 | train |
NCT00000170 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Brief Summary: * To determine whether the success rate with drug treatment (atropine) of amblyopia due to strabismus or anisometropia in patients less than 7 years old is equivalent to the success rate with occlusion (patching) therapy
* To develop more precise estimates of the success rates of amblyopia treatment
* To identify factors that may be associated with successful treatment of amblyopia
* To collect data on the course of treated amblyopia to provide more precise estimates of treatment effects than are now available
Extended Follow up of Study Patients
* Primary: To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years.
* Secondary: To determine whether the long-term visual acuity outcome at age 10 years and at age 15 years differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care
| {
"A": "Arm Label: patching (occlusion therapy); Type: ACTIVE_COMPARATOR; Interventions: Other: patching | Arm Label: binocular games; Type: EXPERIMENTAL; Interventions: Other: binocular games | Intervention Type: OTHER; Name: patching; Assigned to Arm(s): patching (occlusion therapy) | Intervention Type: OTHER; Name: binocular games; Assigned to Arm(s): binocular games",
"B": "Intervention Type: DEVICE; Name: Eye patch; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Spectacles; Assigned to Arm(s): N/A",
"C": "Arm Label: I-BiT Plus; Type: EXPERIMENTAL; Interventions: Device: I-Bit plus | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: I-Bit plus; Assigned to Arm(s): I-BiT Plus",
"D": "Arm Label: Patching; Type: ACTIVE_COMPARATOR; Interventions: Device: Eye Patch | Arm Label: Atropine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atropine | Intervention Type: DRUG; Name: Atropine; Assigned to Arm(s): Atropine | Intervention Type: DEVICE; Name: Eye Patch; Assigned to Arm(s): Patching"
} | D | [
"NCT02365090",
"NCT00091923",
"NCT02810847",
"NCT00000170"
] | 12 | train |
NCT00000171 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This protocol is a multicenter clinical trial of melatonin for sleep disturbances associated with Alzheimer's disease (AD). Frequent nocturnal awakening is a common behavioral symptom of AD. Nighttime wandering and agitated behavior may result in injuries and sleep disruption for caregivers. Alternatives are sorely needed to the currently available sleep medications that have marginal efficacy and serious side effects. Melatonin is a naturally occurring hormone secreted by the pineal gland. It has soporific effects with oral administration and is well tolerated. It enhances sleep in normal older people. Melatonin also may help sleep disturbances associated with AD; however, this remains to be proven.
| {
"A": "Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): N/A",
"B": "Arm Label: Zolpidem CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem CR; Assigned to Arm(s): Zolpidem CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Active Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Tailored Active intervention | Arm Label: Inactive intervention; Type: PLACEBO_COMPARATOR; Interventions: Other: Inactive intervention | Intervention Type: OTHER; Name: Tailored Active intervention; Assigned to Arm(s): Active Intervention | Intervention Type: OTHER; Name: Inactive intervention; Assigned to Arm(s): Inactive intervention",
"D": "Arm Label: Gabapentin Enacarbil (GEn); Type: EXPERIMENTAL; Interventions: Drug: Gabapentin Enacarbil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Gabapentin Enacarbil; Assigned to Arm(s): Gabapentin Enacarbil (GEn) | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo"
} | A | [
"NCT00000171",
"NCT00814502",
"NCT01816152",
"NCT03082755"
] | 13 | train |
NCT00000367 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to design a program to prevent suicide in elderly patients by educating patients, their families, and physicians on depression and suicidal thoughts.
A program to prevent suicide in elderly patients needs to be developed. Since elderly patients frequently have doctor's visits, it may be best to have a suicide prevention program based in the patient's doctor's office.
When an older person visits a primary care physician, he/she will check for signs of depression, including thoughts of suicide. The doctor will speak to the patient about depression and how to recognize it. If the individual is diagnosed with depression, the doctor will offer treatment. During this study, the information the doctor collects will be used to evaluate the effectiveness of the program. The study will last for 2 years.
Eligibility for this study is age of at least 60 years and diagnosis of depression. (Depression required for 920 of the 1200 patients; 280 patients should have no symptoms of depression.)
| {
"A": "Intervention Type: PROCEDURE; Name: Standard Quality Improvement; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Patient-centered Intervention; Assigned to Arm(s): N/A",
"B": "Arm Label: TCSCT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telepsychiatry-based Culturally Sensitive Collaborative Treatment | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Telepsychiatry-based Culturally Sensitive Collaborative Treatment | Intervention Type: BEHAVIORAL; Name: Telepsychiatry-based Culturally Sensitive Collaborative Treatment; Assigned to Arm(s): TCSCT, Usual Care",
"C": "Intervention Type: BEHAVIORAL; Name: care management; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Treatment of depression; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Suicide prevention intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Suicide prevention treatment; Assigned to Arm(s): N/A"
} | D | [
"NCT00243425",
"NCT00854542",
"NCT00246896",
"NCT00000367"
] | 14 | train |
NCT00000367 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to design a program to prevent suicide in elderly patients by educating patients, their families, and physicians on depression and suicidal thoughts.
A program to prevent suicide in elderly patients needs to be developed. Since elderly patients frequently have doctor's visits, it may be best to have a suicide prevention program based in the patient's doctor's office.
When an older person visits a primary care physician, he/she will check for signs of depression, including thoughts of suicide. The doctor will speak to the patient about depression and how to recognize it. If the individual is diagnosed with depression, the doctor will offer treatment. During this study, the information the doctor collects will be used to evaluate the effectiveness of the program. The study will last for 2 years.
Eligibility for this study is age of at least 60 years and diagnosis of depression. (Depression required for 920 of the 1200 patients; 280 patients should have no symptoms of depression.)
| {
"A": "Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Intervention | Arm Label: Attention; Type: EXPERIMENTAL; Interventions: Other: Attention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: Intervention; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Attention; Assigned to Arm(s): Attention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control",
"B": "Arm Label: Routine data collection; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine Data collection | Arm Label: Feedback of patient-reported outcomes; Type: EXPERIMENTAL; Interventions: Other: Routine Data collection, Other: Feedback of patient-reported outcomes | Intervention Type: OTHER; Name: Routine Data collection; Assigned to Arm(s): Feedback of patient-reported outcomes, Routine data collection | Intervention Type: OTHER; Name: Feedback of patient-reported outcomes; Assigned to Arm(s): Feedback of patient-reported outcomes",
"C": "Arm Label: eRAPID intervention; Type: EXPERIMENTAL; Interventions: Device: eRAPID | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: eRAPID; Assigned to Arm(s): eRAPID intervention",
"D": "Intervention Type: DRUG; Name: Treatment of depression; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Suicide prevention intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Suicide prevention treatment; Assigned to Arm(s): N/A"
} | D | [
"NCT01213745",
"NCT01838564",
"NCT02747264",
"NCT00000367"
] | 15 | train |
NCT00000388 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Treatment Study of Children With ADHD
Brief Summary: This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes.
In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
A child may be eligible for this study if he/she:
Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
| {
"A": "Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CONCERTA (methylphenidate HCl) / Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Placebo/ CONCERTA (methylphenidate HCl) | Intervention Type: DRUG; Name: Placebo/ CONCERTA (methylphenidate HCl); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CONCERTA (methylphenidate HCl) / Placebo; Assigned to Arm(s): 1",
"C": "Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A",
"D": "Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (tablet), Drug: Placebo (capsule) | Arm Label: LY2216684 (0.1 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Arm Label: LY2216684 (0.2 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Arm Label: LY2216684 (0.3 mg/kg/day); Type: EXPERIMENTAL; Interventions: Drug: LY2216684 | Intervention Type: DRUG; Name: LY2216684; Assigned to Arm(s): LY2216684 (0.1 mg/kg/day), LY2216684 (0.2 mg/kg/day), LY2216684 (0.3 mg/kg/day) | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo (tablet); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo (capsule); Assigned to Arm(s): Placebo"
} | C | [
"NCT00305370",
"NCT00799409",
"NCT00000388",
"NCT00922636"
] | 16 | train |
NCT00000388 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Treatment Study of Children With ADHD
Brief Summary: This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes.
In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
A child may be eligible for this study if he/she:
Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
| {
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Stimulant medication therapy, Behavioral: Community-based psychosocial treatment | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Group-based behavior therapy, Drug: Stimulant medication therapy | Intervention Type: BEHAVIORAL; Name: Group-based behavior therapy; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Stimulant medication therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Community-based psychosocial treatment; Assigned to Arm(s): 1",
"B": "Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A",
"C": "Arm Label: CBT group; Type: EXPERIMENTAL; Interventions: Behavioral: CBT group | Arm Label: Psychopharmacological treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Psychopharmacological treatment | Intervention Type: DRUG; Name: Psychopharmacological treatment; Assigned to Arm(s): Psychopharmacological treatment | Intervention Type: BEHAVIORAL; Name: CBT group; Assigned to Arm(s): CBT group",
"D": "Arm Label: Business as Usual (BAU); Type: OTHER; Interventions: Other: Business As Usual | Arm Label: Collaborative Life Skills Intervention (CLS); Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Life Skills Intervention (CLS) | Intervention Type: BEHAVIORAL; Name: Collaborative Life Skills Intervention (CLS); Assigned to Arm(s): Collaborative Life Skills Intervention (CLS) | Intervention Type: OTHER; Name: Business As Usual; Assigned to Arm(s): Business as Usual (BAU)"
} | B | [
"NCT00632619",
"NCT00000388",
"NCT02172183",
"NCT01686724"
] | 17 | train |
NCT00000388 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Treatment Study of Children With ADHD
Brief Summary: This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes.
In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
A child may be eligible for this study if he/she:
Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
| {
"A": "Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A",
"B": "Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate HCl, Drug: Risperidone, Behavioral: Parent Management Training (PMT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate HCl, Behavioral: Parent Management Training (PMT), Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate HCl; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Parent Management Training (PMT); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"D": "Arm Label: 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 15 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg); Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Hydrochloride Extended Release Capsules | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride Extended Release Capsules; Assigned to Arm(s): 10 mg, 15 mg, 20 mg, 40 mg, Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
} | A | [
"NCT00000388",
"NCT00151970",
"NCT00796302",
"NCT01239030"
] | 18 | train |
NCT00000388 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Treatment Study of Children With ADHD
Brief Summary: This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes.
In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
A child may be eligible for this study if he/she:
Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
| {
"A": "Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A",
"B": "Arm Label: Methylphenidate, Dexamphetamine, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate, Drug: Placebo, Drug: Dextroamphetamine | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo | Intervention Type: DRUG; Name: Dextroamphetamine; Assigned to Arm(s): Methylphenidate, Dexamphetamine, Placebo",
"C": "Arm Label: Group 1: Guan-Guan+Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guanfacine | Arm Label: Group 2: Placebo-Placebo+DMPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (MPH) | Arm Label: Group 3: Guan-Guan+DMPH (Comb); Type: EXPERIMENTAL; Interventions: Drug: Guanfacine, Drug: Methylphenidate (MPH) | Intervention Type: DRUG; Name: Guanfacine; Assigned to Arm(s): Group 1: Guan-Guan+Placebo, Group 3: Guan-Guan+DMPH (Comb) | Intervention Type: DRUG; Name: Methylphenidate (MPH); Assigned to Arm(s): Group 2: Placebo-Placebo+DMPH, Group 3: Guan-Guan+DMPH (Comb)",
"D": "Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) | Arm Label: Methylphenidate (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Methylphenidate (OROS-MPH) - Placebo | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH); Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate (OROS-MPH) - Placebo; Assigned to Arm(s): Methylphenidate (Placebo)"
} | A | [
"NCT00000388",
"NCT01220440",
"NCT00429273",
"NCT00264797"
] | 19 | train |
NCT00000388 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Treatment Study of Children With ADHD
Brief Summary: This trial is a continuation of the Multimodal Treatment Study of Children with Attention Deficit Hyperactivity Disorder (MTA Study). Continuation Aim 1 is to track the persistence of intervention-related effects as the MTA sample matures into mid-adolescence, including subsequent mental-health and school-related service utilization patterns as a function of MTA treatment experience (treatment assignment) and outcome (degree of treatment success at 14 mo.). Aim 2 is to test specific hypotheses about predictors, mediators, and moderators of long-term outcome among children with ADHD (e.g., comorbidity; family functioning; cognitive skills; peer relations) that may influence adolescent functioning (either independent of or through initial treatment assignment and/or 14-month treatment outcomes); and to compare how these predictors, mediators, and moderators are similar or dissimilar within the normal comparison group. Aim 3 is to track the patterns of risk and protective factors (including their mediation or moderation by initial treatment assignment and/or outcome) involved in early and subsequent stages of developing substance-related disorders and antisocial behavior. Aim 4 is to examine the effect of initial treatment assignment and degree of treatment success on later academic performance, achievement, school conduct, tendency to drop out, and other adverse school outcomes.
In the original MTA design, patients were randomly assigned to 1 of 4 treatment conditions: (1) medication only; (2) psychosocial only; (3) combined (medication and psychosocial); or (4) Assessment-and-Referral condition. All but the latter were treated intensively for 14 months, with assessments for all subjects at baseline, 3, 9, 14, and 24 months. The original MTA design thus provides short-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment.
A child may be eligible for this study if he/she:
Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD).
| {
"A": "Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System (MTS) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo patch | Intervention Type: DRUG; Name: Methylphenidate Transdermal System (MTS); Assigned to Arm(s): A | Intervention Type: OTHER; Name: placebo patch; Assigned to Arm(s): B",
"B": "Arm Label: Adhansia XR; Type: EXPERIMENTAL; Interventions: Drug: Adhansia XR | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Adhansia XR; Assigned to Arm(s): Adhansia XR | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta",
"C": "Arm Label: Medication Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vyvanse, Drug: Methylphenidate | Arm Label: Behavioral Parent Training Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Parent Training | Intervention Type: DRUG; Name: Vyvanse; Assigned to Arm(s): Medication Arm | Intervention Type: BEHAVIORAL; Name: Behavioral Parent Training; Assigned to Arm(s): Behavioral Parent Training Arm | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medication Arm",
"D": "Intervention Type: BEHAVIORAL; Name: Psychosocial treatment; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Anti-ADHD medication; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Assessment-and-Referral; Assigned to Arm(s): N/A"
} | D | [
"NCT00506285",
"NCT04507204",
"NCT02675400",
"NCT00000388"
] | 20 | train |
NCT00000409 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Spine Patient Outcomes Research Trial (SPORT): A Multicenter Randomized Trial for Degenerative Spondylolisthesis (DS) With Spinal Stenosis (SpS) at L4/L5 Level.
Brief Summary: This study tests the effectiveness of different treatments for the three most commonly diagnosed conditions of the lower backbone (lumbar spine). The purpose is to learn which of two commonly prescribed treatments (surgery and nonsurgical therapy) works better for specific types of low back pain.
In this part of the study, we will treat patients with spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) caused by degenerative spondylolisthesis (a condition in which one vertebra, or spinal bone, slips forward on another) with either surgery or nonsurgical methods. This study does not cover the cost of treatment.
| {
"A": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments, Procedure: Fusion--Instrumented, Procedure: Fusion-Non-instrumented | Arm Label: Non-surgical intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical intervention, Surgery | Intervention Type: PROCEDURE; Name: Fusion--Instrumented; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: Fusion-Non-instrumented; Assigned to Arm(s): Surgery",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2",
"C": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery",
"D": "Arm Label: Posterolateral Fusion w/Pedicle Screws; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompression, Device: Posterolateral Fusion and Implantation of Pedicle Screws | Arm Label: coflex Interlaminar Technolgy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompression, Device: Implantation of coflex Interlaminar Technology | Intervention Type: PROCEDURE; Name: Decompression; Assigned to Arm(s): Posterolateral Fusion w/Pedicle Screws, coflex Interlaminar Technolgy | Intervention Type: DEVICE; Name: Posterolateral Fusion and Implantation of Pedicle Screws; Assigned to Arm(s): Posterolateral Fusion w/Pedicle Screws | Intervention Type: DEVICE; Name: Implantation of coflex Interlaminar Technology; Assigned to Arm(s): coflex Interlaminar Technolgy"
} | A | [
"NCT00000409",
"NCT00022776",
"NCT00000411",
"NCT00534235"
] | 21 | train |
NCT00000409 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Spine Patient Outcomes Research Trial (SPORT): A Multicenter Randomized Trial for Degenerative Spondylolisthesis (DS) With Spinal Stenosis (SpS) at L4/L5 Level.
Brief Summary: This study tests the effectiveness of different treatments for the three most commonly diagnosed conditions of the lower backbone (lumbar spine). The purpose is to learn which of two commonly prescribed treatments (surgery and nonsurgical therapy) works better for specific types of low back pain.
In this part of the study, we will treat patients with spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) caused by degenerative spondylolisthesis (a condition in which one vertebra, or spinal bone, slips forward on another) with either surgery or nonsurgical methods. This study does not cover the cost of treatment.
| {
"A": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments, Procedure: Fusion--Instrumented, Procedure: Fusion-Non-instrumented | Arm Label: Non-surgical intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical intervention, Surgery | Intervention Type: PROCEDURE; Name: Fusion--Instrumented; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: Fusion-Non-instrumented; Assigned to Arm(s): Surgery",
"B": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2",
"D": "Arm Label: Vertos mild® Minimally-Invasive Lumbar Decompression; Type: ACTIVE_COMPARATOR; Interventions: Device: MILD® (Minimally Invasive Lumbar Decompression) | Arm Label: Epidural Steroid Injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epidural Steroid Injection | Intervention Type: DEVICE; Name: MILD® (Minimally Invasive Lumbar Decompression); Assigned to Arm(s): Vertos mild® Minimally-Invasive Lumbar Decompression | Intervention Type: DRUG; Name: Epidural Steroid Injection; Assigned to Arm(s): Epidural Steroid Injection"
} | A | [
"NCT00000409",
"NCT00000411",
"NCT00022776",
"NCT00995371"
] | 22 | train |
NCT00000411 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Spine Patient Outcomes Research Trial (SPORT): A Multicenter Trial for Spinal Stenosis (SpS)
Brief Summary: This study tests the effectiveness of different treatments for the three most commonly diagnosed conditions of the lower backbone (lumbar spine). The purpose is to learn which of two commonly prescribed treatments (surgery and nonsurgical therapy) works better for specific types of low back pain. Low back pain is one of the most widely experienced health problems in the United States and the world. It is the second most frequent condition, after the common cold, for which people see a doctor or lose days from work.
In this part of the study, we will treat patients with spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) with a type of surgery known as posterior decompressive laminectomy or with nonsurgical methods. This study does not cover the cost of treatment.
| {
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2",
"B": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery",
"C": "Arm Label: Decompression without fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression without fusion | Arm Label: Decompression with fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression with fusion | Intervention Type: PROCEDURE; Name: Decompression without fusion; Assigned to Arm(s): Decompression without fusion | Intervention Type: PROCEDURE; Name: Decompression with fusion; Assigned to Arm(s): Decompression with fusion",
"D": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments, Procedure: Fusion--Instrumented, Procedure: Fusion-Non-instrumented | Arm Label: Non-surgical intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical intervention, Surgery | Intervention Type: PROCEDURE; Name: Fusion--Instrumented; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: Fusion-Non-instrumented; Assigned to Arm(s): Surgery"
} | B | [
"NCT00022776",
"NCT00000411",
"NCT01994512",
"NCT00000409"
] | 23 | train |
NCT00000411 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Spine Patient Outcomes Research Trial (SPORT): A Multicenter Trial for Spinal Stenosis (SpS)
Brief Summary: This study tests the effectiveness of different treatments for the three most commonly diagnosed conditions of the lower backbone (lumbar spine). The purpose is to learn which of two commonly prescribed treatments (surgery and nonsurgical therapy) works better for specific types of low back pain. Low back pain is one of the most widely experienced health problems in the United States and the world. It is the second most frequent condition, after the common cold, for which people see a doctor or lose days from work.
In this part of the study, we will treat patients with spinal stenosis (a narrowing of spaces in the backbone that results in pressure on the spinal cord and/or nerve roots) with a type of surgery known as posterior decompressive laminectomy or with nonsurgical methods. This study does not cover the cost of treatment.
| {
"A": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments | Arm Label: Non-surgical treatments; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical treatments, Surgery",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Surgical decompression | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Physical therapy | Intervention Type: PROCEDURE; Name: Surgical decompression; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Physical therapy; Assigned to Arm(s): 2",
"C": "Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments, Procedure: Fusion--Instrumented, Procedure: Fusion-Non-instrumented | Arm Label: Non-surgical intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical intervention, Surgery | Intervention Type: PROCEDURE; Name: Fusion--Instrumented; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: Fusion-Non-instrumented; Assigned to Arm(s): Surgery",
"D": "Arm Label: Vertos mild® Minimally-Invasive Lumbar Decompression; Type: ACTIVE_COMPARATOR; Interventions: Device: MILD® (Minimally Invasive Lumbar Decompression) | Arm Label: Epidural Steroid Injection; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epidural Steroid Injection | Intervention Type: DEVICE; Name: MILD® (Minimally Invasive Lumbar Decompression); Assigned to Arm(s): Vertos mild® Minimally-Invasive Lumbar Decompression | Intervention Type: DRUG; Name: Epidural Steroid Injection; Assigned to Arm(s): Epidural Steroid Injection"
} | A | [
"NCT00000411",
"NCT00022776",
"NCT00000409",
"NCT00995371"
] | 24 | train |
NCT00000436 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-Efficacy and High-Intensity Strength Training to Improve Postoperative Rehabilitation of Hip Fracture Patients
Brief Summary: This project will assess the effectiveness of a novel approach involving patient education and strength training to improve functional recovery after a hip fracture. Participants will be randomly assigned to one of two study groups. One group (control group) will receive standard medical care. The other group will participate in a program of patient education and strength training, including an at-home walking program.
| {
"A": "Intervention Type: PROCEDURE; Name: Orthogeriatric intervention; Assigned to Arm(s): N/A",
"B": "Intervention Type: BEHAVIORAL; Name: Self-efficacy and muscle strength training; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: High-intensity strength training; Assigned to Arm(s): N/A",
"C": "Arm Label: Functional training group; Type: EXPERIMENTAL; Interventions: Other: Functional training program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Functional training program; Assigned to Arm(s): Functional training group",
"D": "Arm Label: Enhanced acute medical rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced acute medical rehabilitation | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Enhanced acute medical rehabilitation; Assigned to Arm(s): Enhanced acute medical rehabilitation | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual"
} | B | [
"NCT01009268",
"NCT00000436",
"NCT02780076",
"NCT00951691"
] | 25 | train |
NCT00000457 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.
| {
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 300 mg/day bupropion-sr | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0 mg/day bupropion-sr | Intervention Type: DRUG; Name: 300 mg/day bupropion-sr; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0 mg/day bupropion-sr; Assigned to Arm(s): 2",
"B": "Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban",
"C": "Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
} | D | [
"NCT00218231",
"NCT01806779",
"NCT00143364",
"NCT00000457"
] | 26 | train |
NCT00000457 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.
| {
"A": "Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline",
"D": "Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
} | B | [
"NCT00691483",
"NCT00000457",
"NCT00282984",
"NCT01370356"
] | 27 | train |
NCT00000457 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.
| {
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"B": "Arm Label: High Intensity Counseling + Long Acting NRT + PRN NRT; Type: EXPERIMENTAL; Interventions: Drug: High Intensity Counseling + Long Acting NRT + PRN NRT | Arm Label: High Intensity Counseling + bupropion + PRN NRT; Type: EXPERIMENTAL; Interventions: Drug: High Intensity Counseling + bupropion + PRN NRT | Arm Label: High Intensity Counseling + varenicline + PRN NRT; Type: EXPERIMENTAL; Interventions: Drug: High Intensity Counseling + varenicline + PRN NRT | Arm Label: High Intensity Counseling + Long Acting NRT; Type: EXPERIMENTAL; Interventions: Drug: High Intensity Counseling + Long Acting NRT | Arm Label: High Intensity Counseling + bupropion; Type: EXPERIMENTAL; Interventions: Drug: High Intensity Counseling + bupropion | Arm Label: High Intensity Counseling + varenicline; Type: EXPERIMENTAL; Interventions: Drug: High Intensity Counseling + varenicline | Arm Label: Low Intensity Counseling + Long Acting NRT + PRN NRT; Type: EXPERIMENTAL; Interventions: Drug: Low Intensity Counseling + Long Acting NRT + PRN NRT | Arm Label: Low Intensity Counseling + bupropion + PRN NRT; Type: EXPERIMENTAL; Interventions: Drug: Low Intensity Counseling + bupropion + PRN NRT | Arm Label: Low Intensity Counseling + varenicline + PRN NRT; Type: EXPERIMENTAL; Interventions: Drug: Low Intensity Counseling + varenicline + PRN NRT | Arm Label: Low Intensity Counseling + Long Acting NRT; Type: EXPERIMENTAL; Interventions: Drug: Low Intensity Counseling + Long Acting NRT | Arm Label: Low Intensity Counseling + bupropion; Type: EXPERIMENTAL; Interventions: Drug: Low Intensity Counseling + bupropion | Arm Label: Low Intensity Counseling + varenicline; Type: EXPERIMENTAL; Interventions: Drug: Low Intensity Counseling + varenicline | Intervention Type: DRUG; Name: High Intensity Counseling + Long Acting NRT + PRN NRT; Assigned to Arm(s): High Intensity Counseling + Long Acting NRT + PRN NRT | Intervention Type: DRUG; Name: High Intensity Counseling + bupropion + PRN NRT; Assigned to Arm(s): High Intensity Counseling + bupropion + PRN NRT | Intervention Type: DRUG; Name: High Intensity Counseling + varenicline + PRN NRT; Assigned to Arm(s): High Intensity Counseling + varenicline + PRN NRT | Intervention Type: DRUG; Name: High Intensity Counseling + Long Acting NRT; Assigned to Arm(s): High Intensity Counseling + Long Acting NRT | Intervention Type: DRUG; Name: High Intensity Counseling + bupropion; Assigned to Arm(s): High Intensity Counseling + bupropion | Intervention Type: DRUG; Name: High Intensity Counseling + varenicline; Assigned to Arm(s): High Intensity Counseling + varenicline | Intervention Type: DRUG; Name: Low Intensity Counseling + Long Acting NRT + PRN NRT; Assigned to Arm(s): Low Intensity Counseling + Long Acting NRT + PRN NRT | Intervention Type: DRUG; Name: Low Intensity Counseling + bupropion + PRN NRT; Assigned to Arm(s): Low Intensity Counseling + bupropion + PRN NRT | Intervention Type: DRUG; Name: Low Intensity Counseling + varenicline + PRN NRT; Assigned to Arm(s): Low Intensity Counseling + varenicline + PRN NRT | Intervention Type: DRUG; Name: Low Intensity Counseling + Long Acting NRT; Assigned to Arm(s): Low Intensity Counseling + Long Acting NRT | Intervention Type: DRUG; Name: Low Intensity Counseling + bupropion; Assigned to Arm(s): Low Intensity Counseling + bupropion | Intervention Type: DRUG; Name: Low Intensity Counseling + varenicline; Assigned to Arm(s): Low Intensity Counseling + varenicline",
"C": "Arm Label: 1: Bup+MM; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Medication Management, Drug: placebo patch | Arm Label: 2 Bup+Mayo; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Mayo Counseling, Drug: placebo patch | Arm Label: 3 Patch+MM; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal system, Behavioral: Medication Management, Drug: placebo bupropion | Arm Label: 4 Patch+Mayo; Type: EXPERIMENTAL; Interventions: Drug: nicotine transdermal system, Behavioral: Mayo Counseling, Drug: placebo bupropion | Intervention Type: DRUG; Name: nicotine transdermal system; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: BEHAVIORAL; Name: Medication Management; Assigned to Arm(s): 1: Bup+MM, 3 Patch+MM | Intervention Type: BEHAVIORAL; Name: Mayo Counseling; Assigned to Arm(s): 2 Bup+Mayo, 4 Patch+Mayo | Intervention Type: DRUG; Name: placebo patch; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: DRUG; Name: placebo bupropion; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
} | D | [
"NCT00129311",
"NCT02048917",
"NCT00086411",
"NCT00000457"
] | 28 | train |
NCT00000457 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.
| {
"A": "Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)",
"B": "Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline + nicotine replacement therapy | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo + nicotine replacement therapy | Intervention Type: DRUG; Name: Selegiline + nicotine replacement therapy; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo + nicotine replacement therapy; Assigned to Arm(s): 2"
} | C | [
"NCT01771627",
"NCT01444131",
"NCT00000457",
"NCT00390923"
] | 29 | train |
NCT00000457 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacologic Relapse Prevention for Alcoholic Smokers
Brief Summary: This study will compare the long-term use of bupropion (Wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. The study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. The patch dose is projected to serve as a 100-percent replacement.
| {
"A": "Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A",
"B": "Arm Label: Tailored Intervention Group; Type: EXPERIMENTAL; Interventions: Drug: Nicotine replacement therapy - transdermal nicotine patch, Behavioral: Tailored behavioral intervention, Drug: Nicotine replacement therapy - nicotine gum, Drug: Nicotine replacement therapy - nicotine lozenge, Drug: Bupropion Sustained Release, Drug: Varenicline, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion, Behavioral: Alcohol use risk reduction, Behavioral: Behavioral activation for the treatment of depression, Behavioral: Behavioral management of post-cessation weight gain | Arm Label: Enhanced Standard of Care Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine replacement therapy - transdermal nicotine patch, Behavioral: Tobacco quit line referral, Drug: Nicotine replacement therapy - nicotine gum, Drug: Nicotine replacement therapy - nicotine lozenge, Drug: Bupropion Sustained Release, Drug: Varenicline, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum, Drug: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge, Drug: Combination pharmacotherapy - transdermal nicotine patch + bupropion | Intervention Type: DRUG; Name: Nicotine replacement therapy - transdermal nicotine patch; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Tailored behavioral intervention; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Tobacco quit line referral; Assigned to Arm(s): Enhanced Standard of Care Group | Intervention Type: DRUG; Name: Nicotine replacement therapy - nicotine gum; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Nicotine replacement therapy - nicotine lozenge; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Bupropion Sustained Release; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: DRUG; Name: Combination pharmacotherapy - transdermal nicotine patch + bupropion; Assigned to Arm(s): Enhanced Standard of Care Group, Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Alcohol use risk reduction; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Behavioral activation for the treatment of depression; Assigned to Arm(s): Tailored Intervention Group | Intervention Type: BEHAVIORAL; Name: Behavioral management of post-cessation weight gain; Assigned to Arm(s): Tailored Intervention Group",
"C": "Intervention Type: DRUG; Name: sustained-release bupropion (Zyban(R)); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychodynamic Model Training (R) = PDM(R); Assigned to Arm(s): N/A",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion (Wellbutrin) | Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
} | D | [
"NCT00143364",
"NCT01592695",
"NCT00484692",
"NCT00000457"
] | 30 | train |
NCT00000469 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.
| {
"A": "Arm Label: Carotid Endarterectomy (CEA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Carotid endarterectomy (CEA) | Arm Label: Carotid Stenting (CAS); Type: ACTIVE_COMPARATOR; Interventions: Device: Carotid Stenting (CAS) | Arm Label: Intensive Medical Management - no CEA; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CEA | Arm Label: Intensive Medical Management - no CAS; Type: EXPERIMENTAL; Interventions: Other: Intensive Medical Management - no CAS | Intervention Type: PROCEDURE; Name: Carotid endarterectomy (CEA); Assigned to Arm(s): Carotid Endarterectomy (CEA) | Intervention Type: DEVICE; Name: Carotid Stenting (CAS); Assigned to Arm(s): Carotid Stenting (CAS) | Intervention Type: OTHER; Name: Intensive Medical Management - no CEA; Assigned to Arm(s): Intensive Medical Management - no CEA | Intervention Type: OTHER; Name: Intensive Medical Management - no CAS; Assigned to Arm(s): Intensive Medical Management - no CAS",
"B": "Arm Label: ABT-335 + Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: ABT-335, Other: Atorvastatin | Arm Label: Placebo + Atorvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Atorvastatin | Intervention Type: DRUG; Name: ABT-335; Assigned to Arm(s): ABT-335 + Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Atorvastatin | Intervention Type: OTHER; Name: Atorvastatin; Assigned to Arm(s): ABT-335 + Atorvastatin, Placebo + Atorvastatin",
"C": "Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 2"
} | C | [
"NCT02089217",
"NCT00616772",
"NCT00000469",
"NCT00711919"
] | 31 | train |
NCT00000469 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.
| {
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atenolol, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): 2",
"B": "Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA, Drug: Clopidogrel 75mg | Arm Label: Apixaban group; Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Drug: ASA | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban group | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Apixaban group, Control group | Intervention Type: DRUG; Name: Clopidogrel 75mg; Assigned to Arm(s): Control group",
"C": "Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A",
"D": "Arm Label: A: Rivaroxaban short arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Arm Label: B: Rivaroxaban long arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 MG Oral Tablet [Xarelto] | Intervention Type: DRUG; Name: Rivaroxaban 10 MG Oral Tablet [Xarelto]; Assigned to Arm(s): A: Rivaroxaban short arm, B: Rivaroxaban long arm"
} | C | [
"NCT00185185",
"NCT04229264",
"NCT00000469",
"NCT03522259"
] | 32 | train |
NCT00000469 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine whether warfarin or lovastatin alone or in combination retarded the progression of atherosclerotic plaques in the carotid arteries of high risk individuals with asymptomatic carotid stenosis. Also, to determine if a full scale trial was feasible.
| {
"A": "Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lovastatin; Assigned to Arm(s): N/A",
"B": "Arm Label: Cohort 1 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 1 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 2 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 3 dociparstat; Type: EXPERIMENTAL; Interventions: Drug: Dociparstat sodium | Arm Label: Cohort 3 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dociparstat sodium; Assigned to Arm(s): Cohort 1 dociparstat, Cohort 2 dociparstat, Cohort 3 dociparstat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 placebo, Cohort 2 placebo, Cohort 3 placebo",
"C": "Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux",
"D": "Arm Label: Intermediate dose anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: intermediate dose Enoxaparin/ unfractionated heparin | Arm Label: Standard Prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin | Arm Label: Atorvastatin 20; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin 20mg | Arm Label: Atorvastatin 20 mg Matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched placebo | Intervention Type: DRUG; Name: intermediate dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Intermediate dose anticoagulation | Intervention Type: DRUG; Name: standard prophylactic dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Standard Prophylaxis | Intervention Type: DRUG; Name: Atorvastatin 20mg; Assigned to Arm(s): Atorvastatin 20 | Intervention Type: DRUG; Name: Matched placebo; Assigned to Arm(s): Atorvastatin 20 mg Matched placebo"
} | A | [
"NCT00000469",
"NCT04389840",
"NCT00894283",
"NCT04486508"
] | 33 | train |
NCT00000479 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.
| {
"A": "Arm Label: Left Atrial Ablation; Type: ACTIVE_COMPARATOR; Interventions: Device: Left atrial ablation | Arm Label: Rate or Rhythm Control Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rate or Rhythm Control Therapy | Intervention Type: DEVICE; Name: Left atrial ablation; Assigned to Arm(s): Left Atrial Ablation | Intervention Type: DRUG; Name: Rate or Rhythm Control Therapy; Assigned to Arm(s): Rate or Rhythm Control Therapy",
"B": "Arm Label: Intervention group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention group | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: control group | Intervention Type: PROCEDURE; Name: Intervention group; Assigned to Arm(s): Intervention group | Intervention Type: PROCEDURE; Name: control group; Assigned to Arm(s): control group",
"C": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Drug: Vitamin E | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Behavioral: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Behavioral: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): 2, 3, 4"
} | D | [
"NCT00911508",
"NCT02064114",
"NCT00017953",
"NCT00000479"
] | 34 | train |
NCT00000479 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.
| {
"A": "Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: DASH Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Approaches to Stop Hypertension dietary pattern | Intervention Type: BEHAVIORAL; Name: Dietary Approaches to Stop Hypertension dietary pattern; Assigned to Arm(s): DASH Intervention",
"B": "Arm Label: novel nutritional formula; Type: EXPERIMENTAL; Interventions: Other: medical food with EPA and GLA, vitamins and minerals | Arm Label: Control nutritional product; Type: ACTIVE_COMPARATOR; Interventions: Other: medical food minus EPA and GLA, antioxidant vitamins/minerals | Intervention Type: OTHER; Name: medical food with EPA and GLA, vitamins and minerals; Assigned to Arm(s): novel nutritional formula | Intervention Type: OTHER; Name: medical food minus EPA and GLA, antioxidant vitamins/minerals; Assigned to Arm(s): Control nutritional product",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Drug: Vitamin E | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Behavioral: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Behavioral: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): 2, 3, 4",
"D": "Arm Label: Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo for esomeprazoe; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo proton pump inhibitor | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Placebo proton pump inhibitor; Assigned to Arm(s): Placebo for esomeprazoe"
} | C | [
"NCT01725945",
"NCT01087710",
"NCT00000479",
"NCT00069823"
] | 35 | train |
NCT00000479 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.
| {
"A": "Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Drug: Vitamin E | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Behavioral: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Behavioral: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): 2, 3, 4",
"C": "Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin and mineral supplement, Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Intervention Type: DRUG; Name: vitamin and mineral supplement; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Escherichia coli Endotoxin (LPS); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 100% O2; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: nitroglycerin; Assigned to Arm(s): 1, 2"
} | B | [
"NCT00270647",
"NCT00000479",
"NCT00000541",
"NCT00431691"
] | 36 | train |
NCT00000479 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.
| {
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tibolone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tibolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"B": "Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tamoxifen | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Raloxifene | Intervention Type: DRUG; Name: Raloxifene; Assigned to Arm(s): Group 2 | Intervention Type: DRUG; Name: Tamoxifen; Assigned to Arm(s): Group 1",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Drug: Vitamin E | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Behavioral: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Behavioral: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): 2, 3, 4",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3"
} | C | [
"NCT00519857",
"NCT00003906",
"NCT00000479",
"NCT00352170"
] | 37 | train |
NCT00000479 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
Brief Summary: The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.
| {
"A": "Arm Label: Esomeprazole; Type: EXPERIMENTAL; Interventions: Drug: Esomeprazole | Arm Label: Placebo for esomeprazoe; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo proton pump inhibitor | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Placebo proton pump inhibitor; Assigned to Arm(s): Placebo for esomeprazoe",
"B": "Arm Label: Integrative Medicine; Type: EXPERIMENTAL; Interventions: Behavioral: Integrative Medicine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrative Medicine; Assigned to Arm(s): Integrative Medicine",
"C": "Arm Label: novel nutritional formula; Type: EXPERIMENTAL; Interventions: Other: medical food with EPA and GLA, vitamins and minerals | Arm Label: Control nutritional product; Type: ACTIVE_COMPARATOR; Interventions: Other: medical food minus EPA and GLA, antioxidant vitamins/minerals | Intervention Type: OTHER; Name: medical food with EPA and GLA, vitamins and minerals; Assigned to Arm(s): novel nutritional formula | Intervention Type: OTHER; Name: medical food minus EPA and GLA, antioxidant vitamins/minerals; Assigned to Arm(s): Control nutritional product",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Drug: Vitamin E | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Behavioral: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Aspirin, Behavioral: Placebo | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Placebo | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Placebo; Assigned to Arm(s): 2, 3, 4"
} | D | [
"NCT00069823",
"NCT00843544",
"NCT01087710",
"NCT00000479"
] | 38 | train |
NCT00000481 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the feasibility of recruiting women of different socioeconomic status and minority groups and to determine whether these women could achieve and maintain a modified fat-eating pattern. The full-scale trial sought to determine whether a low-fat diet could decrease the incidence of cancer and coronary heart disease in postmenopausal women. The National Heart, Lung, and Blood Institute contributed funds over a three-year period to measure lipids, lipoproteins, and other cardiovascular disease risk factors.
| {
"A": "Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet",
"B": "Arm Label: Intensive Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Intensive | Arm Label: Routine Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Routine | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control (low saturated fat therapeutic diet) | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Intensive; Assigned to Arm(s): Intensive Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Routine; Assigned to Arm(s): Routine Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (low saturated fat therapeutic diet); Assigned to Arm(s): Control",
"C": "Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2"
} | C | [
"NCT00622960",
"NCT00438425",
"NCT00000481",
"NCT00276939"
] | 39 | train |
NCT00000514 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
| {
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: Pactimibe sulfate; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: reserpine; Assigned to Arm(s): N/A"
} | D | [
"NCT00220961",
"NCT00711919",
"NCT00151788",
"NCT00000514"
] | 40 | train |
NCT00000514 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
| {
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pitavastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): 2",
"B": "Arm Label: Evolocumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Evolocumab, Other: lipid-lowering therapy (LLT) | Arm Label: Standard; Type: PLACEBO_COMPARATOR; Interventions: Other: lipid-lowering therapy (LLT) | Intervention Type: DRUG; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: OTHER; Name: lipid-lowering therapy (LLT); Assigned to Arm(s): Evolocumab, Standard",
"C": "Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: reserpine; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Rosuvastatin calcium; Assigned to Arm(s): N/A"
} | C | [
"NCT00711919",
"NCT04730973",
"NCT00000514",
"NCT00225589"
] | 41 | train |
NCT00000514 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
| {
"A": "Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atenolol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: reserpine; Assigned to Arm(s): N/A",
"B": "N/A",
"C": "Arm Label: Group 1; Type: OTHER; Interventions: Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed | Arm Label: Group 2; Type: OTHER; Interventions: Drug: Group 2: control group with enoxaparin 40mg/d | Intervention Type: DRUG; Name: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Group 2: control group with enoxaparin 40mg/d; Assigned to Arm(s): Group 2",
"D": "Arm Label: Intermediate dose anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: intermediate dose Enoxaparin/ unfractionated heparin | Arm Label: Standard Prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin | Arm Label: Atorvastatin 20; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin 20mg | Arm Label: Atorvastatin 20 mg Matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matched placebo | Intervention Type: DRUG; Name: intermediate dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Intermediate dose anticoagulation | Intervention Type: DRUG; Name: standard prophylactic dose Enoxaparin/ unfractionated heparin; Assigned to Arm(s): Standard Prophylaxis | Intervention Type: DRUG; Name: Atorvastatin 20mg; Assigned to Arm(s): Atorvastatin 20 | Intervention Type: DRUG; Name: Matched placebo; Assigned to Arm(s): Atorvastatin 20 mg Matched placebo"
} | A | [
"NCT00000514",
"NCT04405869",
"NCT04394377",
"NCT04486508"
] | 42 | train |
NCT00000541 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.
| {
"A": "Arm Label: vitamin D3 and calcium carbonate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: Calcium carbonate | Arm Label: Placebo for vitamin D3 and calcium carbonate; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3, Dietary Supplement: Calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Placebo for vitamin D3 and calcium carbonate, vitamin D3 and calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium carbonate; Assigned to Arm(s): Placebo for vitamin D3 and calcium carbonate, vitamin D3 and calcium carbonate",
"B": "Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A",
"C": "Arm Label: Vitamin E + selenium placebo; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Other: selenium placebo | Arm Label: Selenium + vitamin E placebo; Type: EXPERIMENTAL; Interventions: Drug: Selenium, Other: Vitamin E placebo | Arm Label: Vitamin E + selenium; Type: EXPERIMENTAL; Interventions: Drug: Vitamin E, Drug: Selenium | Arm Label: Vitamin E placebo + selenium placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Vitamin E placebo, Other: selenium placebo | Intervention Type: DRUG; Name: Vitamin E; Assigned to Arm(s): Vitamin E + selenium, Vitamin E + selenium placebo | Intervention Type: DRUG; Name: Selenium; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E + selenium | Intervention Type: OTHER; Name: Vitamin E placebo; Assigned to Arm(s): Selenium + vitamin E placebo, Vitamin E placebo + selenium placebo | Intervention Type: OTHER; Name: selenium placebo; Assigned to Arm(s): Vitamin E + selenium placebo, Vitamin E placebo + selenium placebo",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3"
} | B | [
"NCT01052051",
"NCT00000541",
"NCT00006392",
"NCT00352170"
] | 43 | train |
NCT00000541 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.
| {
"A": "Intervention Type: BEHAVIORAL; Name: folic acid (0.8 mg); Assigned to Arm(s): N/A",
"B": "Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A",
"C": "Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A",
"D": "Arm Label: Vitamin B12; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Vitamin B12 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo"
} | B | [
"NCT00110604",
"NCT00000541",
"NCT00272428",
"NCT02457507"
] | 44 | train |
NCT00000541 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.
| {
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: folic acid, vitamin B12 (cyanocobalamin) | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin B6 (pyridoxine) | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: folic acid, vitamin B12 (cyanocobalamin); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: vitamin B6 (pyridoxine); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4",
"C": "Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A"
} | C | [
"NCT00032435",
"NCT00354081",
"NCT00000541",
"NCT00272324"
] | 45 | train |
NCT00000541 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.
| {
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 50ug selenium enriched yeast; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 50ug selenium enriched yeast | Arm Label: 100ug selenium enriched yeast; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 100ug selenium enriched yeast | Arm Label: 200ug selenium enriched yeast; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 200ug selenium enriched yeast | Arm Label: Control onion; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Control onion | Arm Label: Enriched onion; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Enriched onion | Intervention Type: DIETARY_SUPPLEMENT; Name: 50ug selenium enriched yeast; Assigned to Arm(s): 50ug selenium enriched yeast | Intervention Type: DIETARY_SUPPLEMENT; Name: 100ug selenium enriched yeast; Assigned to Arm(s): 100ug selenium enriched yeast | Intervention Type: DIETARY_SUPPLEMENT; Name: 200ug selenium enriched yeast; Assigned to Arm(s): 200ug selenium enriched yeast | Intervention Type: DIETARY_SUPPLEMENT; Name: Control onion; Assigned to Arm(s): Control onion | Intervention Type: DIETARY_SUPPLEMENT; Name: Enriched onion; Assigned to Arm(s): Enriched onion | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: AREDS participants; Type: N/A; Interventions: N/A",
"C": "Intervention Type: DRUG; Name: Natural source Vitamin E 400IU/day; Assigned to Arm(s): N/A",
"D": "Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A"
} | D | [
"NCT00279812",
"NCT00594672",
"NCT00220831",
"NCT00000541"
] | 46 | train |
NCT00000541 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.
| {
"A": "Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A",
"B": "Intervention Type: BEHAVIORAL; Name: ascorbic acid, vitamin E, beta carotene, selenium, zinc; Assigned to Arm(s): N/A",
"C": "Arm Label: Vitamin E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin E | Arm Label: Vitamin C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin C | Arm Label: Multivitamin; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multivitamin | Arm Label: Beta-carotene; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Beta-carotene | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): Vitamin E | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin C; Assigned to Arm(s): Vitamin C | Intervention Type: DIETARY_SUPPLEMENT; Name: Multivitamin; Assigned to Arm(s): Multivitamin | Intervention Type: DIETARY_SUPPLEMENT; Name: Beta-carotene; Assigned to Arm(s): Beta-carotene",
"D": "Arm Label: Lutein/Zeaxanthin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lutein/zeaxanthin | Arm Label: DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA/EPA | Arm Label: Lutein/Zeaxanthin + DHA/EPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lutein/zeaxanthin and DHA/EPA | Arm Label: Placebo/Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lutein/zeaxanthin; Assigned to Arm(s): Lutein/Zeaxanthin | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA/EPA; Assigned to Arm(s): DHA/EPA | Intervention Type: DRUG; Name: Lutein/zeaxanthin and DHA/EPA; Assigned to Arm(s): Lutein/Zeaxanthin + DHA/EPA"
} | A | [
"NCT00000541",
"NCT00272428",
"NCT00270647",
"NCT00345176"
] | 47 | train |
NCT00000541 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS)
Brief Summary: To determine if supplements of vitamin C, vitamin E, beta-carotene, and B-vitamins (a combination of folic acid, vitamins B6 and B12) reduce risk of major cardiovascular events in high risk women with a prior history of atherosclerotic cardiovascular disease. The trial is a companion to the Women's Health Study (WHS), a primary prevention trial of vitamin E and aspirin in a low risk population of women.
| {
"A": "Arm Label: High Dose Multivitamin; Type: EXPERIMENTAL; Interventions: Drug: High Dose Multivitamin | Arm Label: Low Dose Multivitamin; Type: ACTIVE_COMPARATOR; Interventions: Device: Low Dose Multivitamin | Intervention Type: DRUG; Name: High Dose Multivitamin; Assigned to Arm(s): High Dose Multivitamin | Intervention Type: DEVICE; Name: Low Dose Multivitamin; Assigned to Arm(s): Low Dose Multivitamin",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A"
} | C | [
"NCT00064753",
"NCT00032435",
"NCT00000541",
"NCT00106886"
] | 48 | train |
NCT00000542 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
| {
"A": "Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A",
"B": "Arm Label: Chlorthalidone plus amiloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorthalidone plus amiloride | Arm Label: losartan; Type: EXPERIMENTAL; Interventions: Drug: losartan | Intervention Type: DRUG; Name: losartan; Assigned to Arm(s): losartan | Intervention Type: DRUG; Name: Chlorthalidone plus amiloride; Assigned to Arm(s): Chlorthalidone plus amiloride",
"C": "Arm Label: Thiazides; Type: ACTIVE_COMPARATOR; Interventions: Drug: thiazides | Arm Label: Non Tiazidic; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Non thiazidic treatment | Intervention Type: DRUG; Name: thiazides; Assigned to Arm(s): Thiazides | Intervention Type: PROCEDURE; Name: Non thiazidic treatment; Assigned to Arm(s): Non Tiazidic",
"D": "Intervention Type: DRUG; Name: Effects of doxazosin on morning surge in diabetic patients; Assigned to Arm(s): N/A"
} | A | [
"NCT00000542",
"NCT00971165",
"NCT00408512",
"NCT00295555"
] | 49 | train |
NCT00000542 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
| {
"A": "Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: MK0954, /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator : atenolol /Duration of Treatment : 5 Years; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): N/A",
"D": "Arm Label: Candesartan; Type: EXPERIMENTAL; Interventions: Drug: candesartan, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: Lisinopril; Type: EXPERIMENTAL; Interventions: Drug: lisinopril, Drug: nifedipine, long acting, Drug: metoprolol, long-acting | Arm Label: HCTZ; Type: ACTIVE_COMPARATOR; Interventions: Drug: hydrochlorothiazide | Intervention Type: DRUG; Name: candesartan; Assigned to Arm(s): Candesartan | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): Lisinopril | Intervention Type: DRUG; Name: hydrochlorothiazide; Assigned to Arm(s): HCTZ | Intervention Type: DRUG; Name: nifedipine, long acting; Assigned to Arm(s): Candesartan, Lisinopril | Intervention Type: DRUG; Name: metoprolol, long-acting; Assigned to Arm(s): Candesartan, Lisinopril"
} | A | [
"NCT00000542",
"NCT00338260",
"NCT00294710",
"NCT00605072"
] | 50 | train |
NCT00000542 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
| {
"A": "Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Calcium channel blockers (amlodipine, azelnidipine) | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Calcium channel blockers (amlodipine, azelnidipine); Assigned to Arm(s): 2",
"C": "Arm Label: Valsartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valsartan | Arm Label: Amlodipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): Valsartan | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine",
"D": "Intervention Type: DRUG; Name: Valsartan + amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Valsartan + HCTZ; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amlodipine + HCTZ; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Valsartan + amlodipine + HCTZ; Assigned to Arm(s): N/A"
} | A | [
"NCT00000542",
"NCT00134160",
"NCT00129233",
"NCT00327587"
] | 51 | train |
NCT00000542 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
| {
"A": "Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A",
"C": "Arm Label: Rosuvastatin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rosuvastatin | Arm Label: Candesartan/HCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Candesartan/HCT | Intervention Type: DRUG; Name: Candesartan/HCT; Assigned to Arm(s): Candesartan/HCT | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Rosuvastatin",
"D": "Arm Label: Aggrenox, Clopidogrel placebo, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis | Arm Label: Aggrenox placebo, clopidogrel,, Micardis; Type: PLACEBO_COMPARATOR; Interventions: Drug: Micardis, Drug: Aggrenox placebo, Drug: Clopidogrel | Arm Label: Aggrenox, clop placebo, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox, Drug: Clopidogrel placebo, Drug: Micardis placebo | Arm Label: Aggrenox plcebo, clop, micardis placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Aggrenox placebo, Drug: Clopidogrel, Drug: Micardis placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Clopidogrel placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox, Clopidogrel placebo, Micardis | Intervention Type: DRUG; Name: Micardis; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Aggrenox placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox placebo, clopidogrel,, Micardis | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox, clop placebo, micardis placebo | Intervention Type: DRUG; Name: Micardis placebo; Assigned to Arm(s): Aggrenox plcebo, clop, micardis placebo"
} | B | [
"NCT00095654",
"NCT00000542",
"NCT00468923",
"NCT00153062"
] | 52 | train |
NCT00000542 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
| {
"A": "Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A",
"B": "Arm Label: Fosinopril,benidipine combination; Type: EXPERIMENTAL; Interventions: Drug: Fosinopril, Drug: Benidipine | Arm Label: Fosinopril,hydrochlorothiazide combination; Type: EXPERIMENTAL; Interventions: Drug: Fosinopril, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Fosinopril; Assigned to Arm(s): Fosinopril,benidipine combination, Fosinopril,hydrochlorothiazide combination | Intervention Type: DRUG; Name: Benidipine; Assigned to Arm(s): Fosinopril,benidipine combination | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Fosinopril,hydrochlorothiazide combination",
"C": "Arm Label: OM40/AML10; Type: EXPERIMENTAL; Interventions: Drug: Olmesartan medoxomil, Drug: Amlodipine | Arm Label: OM40/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil, Drug: Hydrochlorothiazide | Arm Label: AML10/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, Drug: Hydrochlorothiazide | Arm Label: OM40/AML10/HCTZ25; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olmesartan medoxomil, Drug: Amlodipine, Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Olmesartan medoxomil; Assigned to Arm(s): OM40/AML10, OM40/AML10/HCTZ25, OM40/HCTZ25 | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): AML10/HCTZ25, OM40/AML10, OM40/AML10/HCTZ25 | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): AML10/HCTZ25, OM40/AML10/HCTZ25, OM40/HCTZ25",
"D": "Arm Label: Valsartan; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valsartan | Arm Label: Amlodipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Valsartan; Assigned to Arm(s): Valsartan | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine"
} | A | [
"NCT00000542",
"NCT02646397",
"NCT00649389",
"NCT00129233"
] | 53 | train |
NCT00000548 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To test the hypothesis that low-dose inhaled nitric oxide administered to preterm infants who continue to require mechanical ventilation at 14 days of age will reduce the incidence of chronic lung disease.
| {
"A": "Intervention Type: PROCEDURE; Name: mechanical ventilation; Assigned to Arm(s): N/A",
"B": "Arm Label: Inhaled Nitric Oxide (iNO); Type: EXPERIMENTAL; Interventions: Drug: Inhaled Nitric Oxide (iNO) | Arm Label: Nitrogen (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nitrogen (placebo) | Intervention Type: DRUG; Name: Inhaled Nitric Oxide (iNO); Assigned to Arm(s): Inhaled Nitric Oxide (iNO) | Intervention Type: DRUG; Name: Nitrogen (placebo); Assigned to Arm(s): Nitrogen (placebo)",
"C": "Arm Label: Inhaled Nitric Oxide (INO); Type: ACTIVE_COMPARATOR; Interventions: Drug: Nitric oxide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nitric oxide; Assigned to Arm(s): Inhaled Nitric Oxide (INO) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Inhaled Nitric Oxide (iNO); Type: EXPERIMENTAL; Interventions: Drug: iNO | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: iNO; Assigned to Arm(s): Inhaled Nitric Oxide (iNO) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo"
} | A | [
"NCT00000548",
"NCT00955487",
"NCT00551642",
"NCT00006401"
] | 54 | train |
NCT00000552 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To test if early revascularization, primarily with angioplasty (PTCA) or bypass surgery (CABG), reduced all-cause in-hospital mortality from cardiogenic shock compared to conventional treatment, including thrombolysis.
| {
"A": "Intervention Type: PROCEDURE; Name: angioplasty, transluminal, percutaneous coronary; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: coronary artery bypass; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: thrombolytic therapy; Assigned to Arm(s): N/A",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: L; Type: EXPERIMENTAL; Interventions: Drug: levosimendan | Arm Label: P; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): L | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P",
"D": "Intervention Type: DEVICE; Name: Intra-aortic balloon pump counterpulsation; Assigned to Arm(s): N/A"
} | A | [
"NCT00000552",
"NCT00994825",
"NCT00610350",
"NCT00469248"
] | 55 | train |
NCT00000558 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine whether the addition of angiotensin converting enzyme (ACE) inhibitor to standard therapy in patients with known coronary artery disease and preserved left ventricular function will prevent cardiovascular mortality and reduce the risk of myocardial infarction.
| {
"A": "Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: candesartan cilexetil; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: angiotensin-converting enzyme inhibitors; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Benazepril; Assigned to Arm(s): N/A"
} | C | [
"NCT00153101",
"NCT00242346",
"NCT00000558",
"NCT00270426"
] | 56 | train |
NCT00000559 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine the effects, in postmenopausal women, of hormone replacement therapy on progression/regression of coronary heart disease, as measured by quantitative angiography.
| {
"A": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Micronized 17B-estradiol; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Hormone replacement therapy; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A"
} | D | [
"NCT00000611",
"NCT00115024",
"NCT00252408",
"NCT00000559"
] | 57 | train |
NCT00000559 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To determine the effects, in postmenopausal women, of hormone replacement therapy on progression/regression of coronary heart disease, as measured by quantitative angiography.
| {
"A": "Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A",
"B": "Arm Label: Previous HT use and cognition; Type: N/A; Interventions: N/A",
"C": "Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conjugated equine estrogens 0.45 mg/day, Drug: Transdermal estradiol, 50 mcg/day, Drug: Micronized progesterone, 200 mg/day x 12 d/month, Drug: CEE, progesterone, transdermal patch or the placebo | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: CEE , progesterone, estradiol patch or placebo for each, Drug: CEE, progesterone, transdermal patch or the placebo | Intervention Type: DRUG; Name: Conjugated equine estrogens 0.45 mg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Transdermal estradiol, 50 mcg/day; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Micronized progesterone, 200 mg/day x 12 d/month; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: CEE , progesterone, estradiol patch or placebo for each; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: CEE, progesterone, transdermal patch or the placebo; Assigned to Arm(s): Arm 1, Arm 2",
"D": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A"
} | A | [
"NCT00000559",
"NCT01124773",
"NCT00154180",
"NCT00000611"
] | 58 | train |
NCT00000575 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Management Program
Brief Summary: The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
| {
"A": "Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide",
"B": "Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II",
"C": "Intervention Type: DRUG; Name: ciclesonide; Assigned to Arm(s): N/A",
"D": "Arm Label: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Arm Label: fluticasone propionate 2 x 100 mcg; Type: OTHER; Interventions: Drug: fluticasone propionate 2 x 100 mcg | Intervention Type: DRUG; Name: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Assigned to Arm(s): Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Intervention Type: DRUG; Name: fluticasone propionate 2 x 100 mcg; Assigned to Arm(s): fluticasone propionate 2 x 100 mcg"
} | A | [
"NCT00000575",
"NCT00459368",
"NCT00270348",
"NCT00197106"
] | 59 | train |
NCT00000575 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Management Program
Brief Summary: The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
| {
"A": "Intervention Type: DRUG; Name: Pulmicort (budesonide) pMDI; Assigned to Arm(s): N/A",
"B": "Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide",
"C": "Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS",
"D": "Intervention Type: DRUG; Name: beclomethasone/salbutamol combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beclomethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): N/A"
} | B | [
"NCT00234390",
"NCT00000575",
"NCT00394329",
"NCT00382889"
] | 60 | train |
NCT00000575 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Management Program
Brief Summary: The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
| {
"A": "Arm Label: Sequence #1; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #2; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #3; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #4; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #5; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Arm Label: Sequence #6; Type: EXPERIMENTAL; Interventions: Drug: fluticasone propionate + montelukast, Drug: fluticasone propionate, Drug: fluticasone propionate + salmeterol | Intervention Type: DRUG; Name: fluticasone propionate + montelukast; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6 | Intervention Type: DRUG; Name: fluticasone propionate + salmeterol; Assigned to Arm(s): Sequence #1, Sequence #2, Sequence #3, Sequence #4, Sequence #5, Sequence #6",
"B": "Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide",
"C": "Arm Label: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Arm Label: fluticasone propionate 2 x 100 mcg; Type: OTHER; Interventions: Drug: fluticasone propionate 2 x 100 mcg | Intervention Type: DRUG; Name: Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg; Assigned to Arm(s): Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg | Intervention Type: DRUG; Name: fluticasone propionate 2 x 100 mcg; Assigned to Arm(s): fluticasone propionate 2 x 100 mcg",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone propionate/Formoterol fumarate 250/10 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Formoterol fumarate 100/10 | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 250 | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol fumarate 10 | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol fumarate 250/10; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: Fluticasone propionate/Formoterol fumarate 100/10; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Fluticasone propionate 250; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Formoterol fumarate 10; Assigned to Arm(s): 4"
} | B | [
"NCT00395304",
"NCT00000575",
"NCT00197106",
"NCT00393952"
] | 61 | train |
NCT00000575 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Childhood Asthma Management Program
Brief Summary: The purpose of this study is to evaluate the long term effects of anti-inflammatory therapy compared to bronchodilator therapy on the course of asthma, particularly on lung function and bronchial hyperresponsiveness, and on physical and psychosocial growth and development.
| {
"A": "Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4",
"C": "Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS",
"D": "Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide"
} | D | [
"NCT00384189",
"NCT00163449",
"NCT00394329",
"NCT00000575"
] | 62 | train |
NCT00000592 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.
| {
"A": "Arm Label: Stem Cell Transplantation; Type: EXPERIMENTAL; Interventions: Procedure: Stem cell transplantation | Arm Label: Transfusion program; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion program | Intervention Type: PROCEDURE; Name: Stem cell transplantation; Assigned to Arm(s): Stem Cell Transplantation | Intervention Type: PROCEDURE; Name: Transfusion program; Assigned to Arm(s): Transfusion program",
"B": "Arm Label: Standard Therapy: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea",
"C": "Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A",
"D": "Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group"
} | C | [
"NCT01340404",
"NCT01531387",
"NCT00000592",
"NCT00072761"
] | 63 | train |
NCT00000592 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.
| {
"A": "Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A",
"B": "Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group",
"D": "Arm Label: Blood Transfusion Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Biological: Single blood transfusion | Arm Label: Standard Care Trial Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Standard Care Observational Cohort; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BIOLOGICAL; Name: Single blood transfusion; Assigned to Arm(s): Blood Transfusion Trial Cohort | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care Observational Cohort, Standard Care Trial Cohort"
} | A | [
"NCT00000592",
"NCT01794000",
"NCT00072761",
"NCT00951808"
] | 64 | train |
NCT00000592 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.
| {
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea, Procedure: Phlebotomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red Cell Transfusions, Procedure: Iron Chelation | Intervention Type: PROCEDURE; Name: Red Cell Transfusions; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Iron Chelation; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Phlebotomy; Assigned to Arm(s): 1",
"B": "Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A",
"C": "Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm",
"D": "Arm Label: Transfusion Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transfusion therapy | Arm Label: Observation Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: transfusion therapy; Assigned to Arm(s): Transfusion Group"
} | B | [
"NCT00122980",
"NCT00000592",
"NCT01425307",
"NCT00072761"
] | 65 | train |
NCT00000592 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To reduce episodes of first time stroke by 75 percent in children with sickle cell anemia by the administration of prophylactic transfusion therapy.
| {
"A": "Intervention Type: PROCEDURE; Name: Blood Transfusion; Assigned to Arm(s): N/A",
"B": "Arm Label: Standard Therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Treatment Arm",
"C": "Intervention Type: PROCEDURE; Name: blood transfusion; Assigned to Arm(s): N/A",
"D": "Arm Label: Standard Therapy: Observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hydroxyurea; Type: EXPERIMENTAL; Interventions: Drug: Hydroxyurea | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea"
} | C | [
"NCT00006182",
"NCT01425307",
"NCT00000592",
"NCT01531387"
] | 66 | train |
NCT00000606 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the long term efficacy, morbidity and mortality associated with medical therapy with lung volume reduction surgery (LVRS) as compared to medical therapy alone and to define patient selection criteria. The trial, conducted in conjunction with a patient registry, is supported by the NHLBI, the Centers for Medicare and Medicaid Services (CMS), and the Agency for Healthcare Research and Quality (AHRQ).
| {
"A": "Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham control | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Exhale® Drug-Eluting Stent | Intervention Type: DEVICE; Name: Exhale® Drug-Eluting Stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham control; Assigned to Arm(s): 2",
"B": "Arm Label: Medical management; Type: NO_INTERVENTION; Interventions: Device: IBV Valve | Intervention Type: DEVICE; Name: IBV Valve; Assigned to Arm(s): Medical management",
"C": "Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): N/A",
"D": "Arm Label: Chartis System-EBV Treatment; Type: OTHER; Interventions: Device: Chartis System, Device: Endobronchial Valve (EBV) Treatment | Intervention Type: DEVICE; Name: Chartis System; Assigned to Arm(s): Chartis System-EBV Treatment | Intervention Type: DEVICE; Name: Endobronchial Valve (EBV) Treatment; Assigned to Arm(s): Chartis System-EBV Treatment"
} | C | [
"NCT00391612",
"NCT00880724",
"NCT00000606",
"NCT01101958"
] | 67 | train |
NCT00000606 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate the long term efficacy, morbidity and mortality associated with medical therapy with lung volume reduction surgery (LVRS) as compared to medical therapy alone and to define patient selection criteria. The trial, conducted in conjunction with a patient registry, is supported by the NHLBI, the Centers for Medicare and Medicaid Services (CMS), and the Agency for Healthcare Research and Quality (AHRQ).
| {
"A": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel | Intervention Type: DRUG; Name: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel; Assigned to Arm(s): Group 1, Group 2",
"B": "Arm Label: Lung volume reduction surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung volume reduction surgery | Arm Label: No lung volume reduction surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): Lung volume reduction surgery",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: awake nonresectional LVRS | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nonawake resectional LVRS | Intervention Type: PROCEDURE; Name: awake nonresectional LVRS; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Nonawake resectional LVRS; Assigned to Arm(s): 2",
"D": "Intervention Type: PROCEDURE; Name: Lung volume reduction surgery; Assigned to Arm(s): N/A"
} | D | [
"NCT00515164",
"NCT01020344",
"NCT00566839",
"NCT00000606"
] | 68 | train |
NCT00000609 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To compare conventional treatment of congestive heart failure (CHF) with two experimental interventions: amiodarone and an implantable cardioverter-defibrillator (ICD).
| {
"A": "Intervention Type: DRUG; Name: amiodarone; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: defibrillators, implantable; Assigned to Arm(s): N/A",
"B": "N/A",
"C": "Arm Label: Biventricular pacing; Type: EXPERIMENTAL; Interventions: Device: Cardiac Resynchronization Therapy (CRT) | Arm Label: Right ventricular pacing; Type: ACTIVE_COMPARATOR; Interventions: Device: Cardiac Resynchronization Therapy (CRT) | Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy (CRT); Assigned to Arm(s): Biventricular pacing | Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy (CRT); Assigned to Arm(s): Right ventricular pacing",
"D": "Intervention Type: DEVICE; Name: Cardiac Resynchronization Therapy with & without defibrillator; Assigned to Arm(s): N/A"
} | A | [
"NCT00000609",
"NCT01992458",
"NCT00267098",
"NCT00180258"
] | 69 | train |
NCT00000611 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
| {
"A": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"B": "Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A",
"C": "Arm Label: Intervention; Type: N/A; Interventions: Behavioral: educational/counseling intervention, Behavioral: therapeutic dietary intervention | Arm Label: Control; Type: N/A; Interventions: Behavioral: therapeutic dietary intervention | Intervention Type: BEHAVIORAL; Name: educational/counseling intervention; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: therapeutic dietary intervention; Assigned to Arm(s): Control, Intervention",
"D": "Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet"
} | A | [
"NCT00000611",
"NCT00160108",
"NCT00003787",
"NCT00622960"
] | 70 | train |
NCT00000611 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
| {
"A": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"B": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"C": "Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP",
"D": "Arm Label: Physical Activity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Activity | Arm Label: Successful Aging; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Successful Aging | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Physical Activity | Intervention Type: BEHAVIORAL; Name: Successful Aging; Assigned to Arm(s): Successful Aging"
} | A | [
"NCT00000611",
"NCT00017953",
"NCT01206062",
"NCT01072500"
] | 71 | train |
NCT00000611 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
| {
"A": "Arm Label: Low Carb; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low- Carbohydrate -Atkins Diet | Arm Label: Low Calorie; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Calorie Diet | Intervention Type: BEHAVIORAL; Name: Low- Carbohydrate -Atkins Diet; Assigned to Arm(s): Low Carb | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet; Assigned to Arm(s): Low Calorie",
"B": "Arm Label: Intensive Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Intensive | Arm Label: Routine Portfolio; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Dietary Portfolio - Routine | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Control (low saturated fat therapeutic diet) | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Intensive; Assigned to Arm(s): Intensive Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Portfolio - Routine; Assigned to Arm(s): Routine Portfolio | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (low saturated fat therapeutic diet); Assigned to Arm(s): Control",
"C": "Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A"
} | D | [
"NCT00143936",
"NCT00438425",
"NCT00274729",
"NCT00000611"
] | 72 | train |
NCT00000611 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
| {
"A": "Arm Label: BALANCE group; Type: EXPERIMENTAL; Interventions: Behavioral: BALANCE | Arm Label: Control Diet group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control diet | Intervention Type: BEHAVIORAL; Name: BALANCE; Assigned to Arm(s): BALANCE group | Intervention Type: BEHAVIORAL; Name: Control diet; Assigned to Arm(s): Control Diet group",
"B": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"C": "Arm Label: DASH diet; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet | Arm Label: DASH diet plus Weight loss; Type: EXPERIMENTAL; Interventions: Behavioral: DASH diet plus Weight loss | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: DASH diet; Assigned to Arm(s): DASH diet | Intervention Type: BEHAVIORAL; Name: DASH diet plus Weight loss; Assigned to Arm(s): DASH diet plus Weight loss",
"D": "Arm Label: Stanol ester; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Stanol ester spread | Arm Label: Placebo spread; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo spread | Arm Label: Mediterranean diet group; Type: OTHER; Interventions: Dietary Supplement: Mediterranean Diet | Intervention Type: DIETARY_SUPPLEMENT; Name: Stanol ester spread; Assigned to Arm(s): Stanol ester | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo spread; Assigned to Arm(s): Placebo spread | Intervention Type: DIETARY_SUPPLEMENT; Name: Mediterranean Diet; Assigned to Arm(s): Mediterranean diet group"
} | B | [
"NCT01620398",
"NCT00000611",
"NCT00571844",
"NCT00793364"
] | 73 | train |
NCT00000611 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
| {
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Mediterranean diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-fat diet | Intervention Type: OTHER; Name: Mediterranean diet; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Low-fat diet; Assigned to Arm(s): 2",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2",
"C": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"D": "Intervention Type: BEHAVIORAL; Name: Diet counseling; Assigned to Arm(s): N/A"
} | C | [
"NCT00725257",
"NCT00276939",
"NCT00000611",
"NCT00230919"
] | 74 | train |
NCT00000611 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
| {
"A": "Intervention Type: DRUG; Name: Hormone replacement therapy; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Micronized 17B-estradiol; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estradiol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: medroxyprogesterone; Assigned to Arm(s): N/A"
} | B | [
"NCT00252408",
"NCT00000611",
"NCT00115024",
"NCT00000559"
] | 75 | train |
NCT00000611 | Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To address cardiovascular disease, cancer, and osteoporosis, the most common causes of death, disability, and impaired quality of life in postmenopausal women. The three major components of the WHI are: a randomized controlled clinical trial of hormone replacement therapy (HRT), dietary modification (DM), and calcium/vitamin D supplementation (CaD); an observational study (OS); and a community prevention study (CPS). On October 1, 1997, administration of the WHI was transferred to the NHLBI where it is conducted as a consortium effort led by the NHLBI in cooperation with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Cancer Institute (NCI), and the National Institute on Aging (NIA).
| {
"A": "Arm Label: Placeco + exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Placebo + exercise | Arm Label: Phytoestrogens without exercise; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Phytoestrogens without exercise | Arm Label: Phytoestrogens + exercise; Type: EXPERIMENTAL; Interventions: Other: Phytoestrogens + exercise | Arm Label: Placebo without exercise; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Placebo + exercise; Assigned to Arm(s): Placeco + exercise | Intervention Type: DIETARY_SUPPLEMENT; Name: Phytoestrogens without exercise; Assigned to Arm(s): Phytoestrogens without exercise | Intervention Type: OTHER; Name: Phytoestrogens + exercise; Assigned to Arm(s): Phytoestrogens + exercise",
"B": "Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program",
"C": "Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A",
"D": "Arm Label: Non-Exercise Control Group; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 4-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 8-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Arm Label: 12-kcal/kg Energy Expenditure per week; Type: N/A; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): 12-kcal/kg Energy Expenditure per week, 4-kcal/kg Energy Expenditure per week, 8-kcal/kg Energy Expenditure per week, Non-Exercise Control Group"
} | C | [
"NCT01048606",
"NCT00091988",
"NCT00000611",
"NCT00011193"
] | 76 | train |
End of preview. Expand
in Data Studio
Dataset website: https://ryanwangzf.github.io/projects/trialpanorama
- Downloads last month
- 62